비교리스트

 카트 문의
시장보고서
상품코드
1421685

중증 근무력증 치료제 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 약물 유형별, 진단별, 치료별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)

Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 중증 근무력증 치료제 세계 시장 규모는 2032년까지 23억 2,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

중증 근무력증은 면역계가 신경과 근육의 연결을 공격하여 근력 약화와 피로를 유발하는 자가면역성 신경근 질환입니다.

중증근무력증(MG) 치료 시장은 최근 몇 가지 요인으로 인해 꾸준히 성장하고 있습니다. 진단 건수 증가, 질병에 대한 이해 증가, 치료법의 발전 등이 그것입니다. 제약회사들도 연구개발에 투자하여 보다 효과적이고 부작용이 적은 혁신적인 치료법을 도입하고 있습니다. 생물학적 제제 및 분자 표적 치료제의 출현으로 보다 안전하고 효율적인 치료법에 대한 수요가 세계 MG 치료 시장의 성장을 지속적으로 견인할 것으로 예상됩니다.

코로나19 팬데믹은 중증 근무력증(MG) 질환 시장에 큰 영향을 미쳤으며, MG는 의료 시스템이 코로나19 환자에 집중되면서 진단 및 치료 지연으로 인한 어려움에 직면했습니다. 그러나 팬데믹은 원격 의료와 원격 모니터링의 활용을 가속화하여 MG 환자가 바이러스에 대한 노출을 최소화하면서 의료진과 상담할 수 있는 중요한 도구를 제공했습니다. 제약업계는 이러한 혼란에도 불구하고 MG에 대한 새로운 치료법을 계속 개발하여 치료 옵션을 개선할 수 있는 희망을 가져다주고 있습니다.

또한, 2021년 6월 국립의학도서관(National Library of Medicine)에 발표된 연구에 따르면, 관상동맥질환(CAD)이 전 세계인의 건강에 미치는 영향은 연간 약 610,000명의 사망자를 발생시키며, 미국 내 사망자 4명 중 1명이 CAD로 인해 사망하는 것으로 추정되고 있습니다. CAD의 발병률이 증가함에 따라, 이 시급한 의료 수요를 해결하기 위한 효과적인 관상동맥 스텐트 장치에 대한 수요가 증가하고 있습니다. 결과적으로 이러한 요인은 예측 기간 동안 관상동맥 스텐트에 대한 수요를 촉진할 것으로 예상됩니다.

중증 근무력증 시장 보고서 하이라이트

  • IIVg 부문은 2022년 중증 근무력증 시장에서 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 정맥 내 면역글로불린 주입 요법(IVIg)은 건강한 기증자로부터 얻은 면역글로불린 항체를 주입하는 것을 포함합니다. 이 치료법은 면역 체계를 일시적으로 조절하고 중증 근무력증(MG)의 증상을 관리하는 데 매우 효과적인 것으로 밝혀졌습니다.
  • 예측 기간 동안 병원 부문이 가장 높은 시장 점유율을 차지했습니다. 병원 약국은 다양한 약물의 배포 및 적용을 통해 중증 근무력증(MG) 관리에 중요한 역할을 하고 있으며, MG 사례가 증가함에 따라 병원에서 치료를 받는 환자가 증가함에 따라 병원 약국에서 MG 특이적 약물에 대한 수요가 증가하고 있습니다.
  • 2022년 북미가 가장 큰 시장을 차지했습니다. 중증 근무력증(MG)은 북미에서 현저한 유병률을 보이고 있으며, 북미는 치료에서 중요한 위치를 차지하고 있습니다. 이 지역의 탄탄한 의료 인프라는 상당수의 중증 근무력증 환자를 쉽게 식별하고 관리할 수 있어 제약회사와 연구자들의 관심을 끌고 있습니다. 또한, 탄력적인 의료비 상환 프레임워크는 많은 고가의 중증근무력증 치료제에 대한 적용을 효과적으로 확대하여 환자의 접근성을 높이고 신속한 개입을 촉진하고 있습니다.
  • 아태지역은 근위축증 치료제 시장에서 가장 빠른 성장세를 보이고 있습니다. 이 시장의 성장을 주도하는 요인은 여러 가지가 있지만, 특히 민관 협력의 노력이 가장 큰 요인으로 꼽힙니다. 이러한 노력은 주로 신경근육질환의 효과적인 치료법 개발과 보급에 초점을 맞추었습니다. 또한, 교육 캠페인과 정보 보급 활동을 통해 신경근육질환에 대한 일반 대중의 인식이 높아진 것도 시장 확대에 박차를 가하고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 중증근무력증 치료 시장 인사이트

  • 중증근무력증 치료-업계 현황
  • 중증근무력증 치료 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • PESTLE 분석
  • 중증근무력증 치료 업계 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 중증근무력증 치료 시장, 약제 클래스별

  • 주요 조사 결과
  • 서론
  • IVIg
  • 단클론항체
  • 면역억제제
  • 콜린에스테라아제 억제제
  • 코르티코스테로이드

제6장 세계의 중증근무력증 치료 시장, 진단별

  • 주요 조사 결과
  • 서론
  • 혈액검사
  • 전기 진단
  • 에드로포늄 테스트

제7장 세계의 중증근무력증 치료 시장, 치료별

  • 주요 조사 결과
  • 서론
  • 수술
  • 약제
  • HSCT

제8장 세계의 중증근무력증 치료 시장, 유통 채널별

  • 주요 조사 결과
  • 서론
  • 온라인 약국
  • 병원 약국
  • 소매 약국

제9장 세계의 중증근무력증 치료 시장, 지역별

  • 주요 조사 결과
  • 서론
    • 중증근무력증 치료 시장 평가, 지역,2019-2032년
  • 중증근무력증 치료 시장 - 북미
    • 북미 : 중증근무력증 치료 시장, 약제 클래스별, 2019-2032년
    • 북미 : 중증근무력증 치료 시장, 유통 채널별, 2019-2032년
    • 북미 : 중증근무력증 치료 시장, 진단별, 2019-2032년
    • 북미 : 중증근무력증 치료 시장, 치료별, 2019-2032년
    • 중증근무력증 치료 시장 - 미국
    • 중증근무력증 치료 시장 - 캐나다
  • 중증근무력증 치료 시장 - 유럽
    • 유럽 : 중증근무력증 치료 시장, 약제 클래스별, 2019-2032년
    • 유럽 : 중증근무력증 치료 시장, 유통 채널별, 2019-2032년
    • 유럽 : 중증근무력증 치료 시장, 진단별, 2019-2032년
    • 유럽 : 중증근무력증 치료 시장, 치료별, 2019-2032년
    • 중증근무력증 치료 시장 - 영국
    • 중증근무력증 치료 시장 - 프랑스
    • 중증근무력증 치료 시장 - 독일
    • 중증근무력증 치료 시장 - 이탈리아
    • 중증근무력증 치료 시장 - 스페인
    • 중증근무력증 치료 시장 - 네덜란드
    • 중증근무력증 치료 시장 - 러시아
  • 중증근무력증 치료 시장 - 아시아태평양
    • 아시아태평양 : 중증근무력증 치료 시장, 약제 클래스별, 2019-2032년
    • 아시아태평양 : 중증근무력증 치료 시장, 유통 채널별, 2019-2032년
    • 아시아태평양 : 중증근무력증 치료 시장, 진단별, 2019-2032년
    • 아시아태평양 : 중증근무력증 치료 시장, 치료별, 2019-2032년
    • 중증근무력증 치료 시장 - 중국
    • 중증근무력증 치료 시장 - 인도
    • 중증근무력증 치료 시장 - 일본
    • 중증근무력증 치료 시장 - 말레이시아
    • 중증근무력증 치료 시장 - 인도네시아
    • 중증근무력증 치료 시장 - 한국
  • 중증근무력증 치료 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 중증근무력증 치료 시장, 약제 클래스별, 2019-2032년
    • 중동 및 아프리카 : 중증근무력증 치료 시장, 유통 채널별, 2019-2032년
    • 중동 및 아프리카 : 중증근무력증 치료 시장, 진단별, 2019-2032년
    • 중동 및 아프리카 : 중증근무력증 치료 시장, 치료별, 2019-2032년
    • 중증근무력증 치료 시장 - 사우디아라비아
    • 중증근무력증 치료 시장 - 남아프리카
    • 중증근무력증 치료 시장 - 이스라엘
    • 중증근무력증 치료 시장 - UAE
  • 중증근무력증 치료 시장 - 라틴아메리카
    • 라틴아메리카 : 중증근무력증 치료 시장, 약제 클래스별, 2019-2032년
    • 라틴아메리카 : 중증근무력증 치료 시장, 유통 채널별, 2019-2032년
    • 라틴아메리카 : 중증근무력증 치료 시장, 진단별, 2019-2032년
    • 라틴아메리카 : 중증근무력증 치료 시장, 치료별, 2019-2032년
    • 중증근무력증 치료 시장 - 멕시코
    • 중증근무력증 치료 시장 - 브라질
    • 중증근무력증 치료 시장 - 아르헨티나

제10장 경쟁 구도

  • 확장 및 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제11장 기업 개요

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.(formerly Valeant Pharmaceuticals)
  • Bristol-Myers Squibb Company(now part of Bristol Myers Squibb)
  • Grifols, S.A.
  • Mylan N.V.(now part of Viatris Inc.)
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holdings AG(including its subsidiary, Genentech)
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
LSH 24.02.19

The global myasthenia gravis disease treatment market size is expected to reach USD 2.32 billion by 2032, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia gravis is an autoimmune neuromuscular disorder that causes muscle weakness and fatigue due to the immune system attacking the connection between nerves and muscles.

The market for treating Myasthenia Gravis (MG) has been growing steadily in recent years due to several factors. There has been an increase in the number of diagnoses, better understanding of the disease, and advancements in treatment options. Pharmaceutical companies have also invested in research and development to introduce innovative therapies that offer more effectiveness and fewer side effects. With the emergence of biologics and targeted therapies, the demand for safer and more efficient treatments is expected to continue driving the growth of the global MG treatment market.

The COVID-19 pandemic had a significant impact on the Myasthenia Gravis (MG) disease market. MG faced challenges due to the healthcare system's focus on COVID-19 patients, causing delays in diagnosis and treatment. However, the pandemic accelerated the use of telemedicine and remote monitoring, which provided crucial tools for MG patients to consult with healthcare providers while minimizing virus exposure. The pharmaceutical industry continued to develop novel therapies for MG despite disruptions, offering hope for improved treatment options.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective coronary stent devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for coronary stents throughout the forecast period.

Myasthenia Gravis Disease Market Report Highlights

  • In 2022, the IVIg segment held the largest revenue share in the myasthenia gravis disease market. Intravenous Immunoglobulin (IVIg) treatment involves the infusion of immunoglobulin antibodies obtained from healthy donors. This medical procedure has been found to be highly effective in temporarily regulating the immune system and managing the symptoms of Myasthenia Gravis (MG).
  • The hospital segment accounted for the highest market share during the forecast period. Hospital pharmacies play a vital role in managing Myasthenia Gravis (MG) through the distribution and application of various medications. As MG cases increase, more patients seek treatment in hospitals, leading to a higher demand for MG-specific drugs in hospital pharmacies.
  • In 2022, North America dominated the largest market. Myasthenia gravis (MG) exhibits a significant prevalence in North America, positioning it as a key player in the landscape of treatment. The region's robust healthcare infrastructure facilitates the identification and management of a substantial number of MG cases, drawing the interest of pharmaceutical firms and researchers alike. Furthermore, the resilient healthcare reimbursement framework effectively extends coverage to numerous costly MG treatments, enhancing their accessibility for patients and promoting prompt intervention.
  • The Asia-Pacific region accounted for the fastest growth in the myasthenia disease treatment market. The market's growth is driven by various factors, notably the concerted efforts of both public and private entities. These endeavors primarily focus on advancing and distributing effective treatments for neuromuscular disorders. Moreover, the market's expansion is fueled by increasing public awareness of neuromuscular conditions, supported by educational campaigns and information dissemination initiatives.
  • The global key market players include: AbbVie Inc., Alexion Pharmaceuticals, Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Grifols, S.A., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holdings AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the myasthenia disease treatment market report based on drug class, diagnosis, treatment, distribution channel, and region:

Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • IVIg
  • Monoclonal Antibodies
  • Immunosuppressants
  • Cholinesterase Inhibitors
  • Corticosteroids

Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

  • Blood Tests
  • Electrodiagnosis
  • Edrophonium Test

Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Surgery
  • Medication
  • HSCT

Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Treatment Market Insights

  • 4.1. Myasthenia Gravis Disease Treatment - Industry Snapshot
  • 4.2. Myasthenia Gravis Disease Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Improvement in therapies and treatment options across the Globe will Facilitate market growth
      • 4.2.1.2. Inflation of healthcare infrastructure bill bolster market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High treatment cost will hamper on the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Myasthenia Gravis Disease Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. IVIg
    • 5.3.1. Global Myasthenia Gravis Disease Treatment Market, by IVIg, by Region, 2019-2032 (USD Billion)
  • 5.4. Monoclonal Antibodies
    • 5.4.1. Global Myasthenia Gravis Disease Treatment Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
  • 5.5. Immunosuppressants
    • 5.5.1. Global Myasthenia Gravis Disease Treatment Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
  • 5.6. Cholinesterase Inhibitors
    • 5.6.1. Global Myasthenia Gravis Disease Treatment Market, by Cholinesterase Inhibitors, by Region, 2019-2032 (USD Billion)
  • 5.7. Corticosteroids
    • 5.7.1. Global Myasthenia Gravis Disease Treatment Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)

6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • 6.3. Blood Tests
    • 6.3.1. Global Myasthenia Gravis Disease Treatment Market, by Blood Tests, by Region, 2019-2032 (USD Billion)
  • 6.4. Electrodiagnosis
    • 6.4.1. Global Myasthenia Gravis Disease Treatment Market, by Electrodiagnosis, by Region, 2019-2032 (USD Billion)
  • 6.5. Edrophonium Test
    • 6.5.1. Global Myasthenia Gravis Disease Treatment Market, by Edrophonium Test, by Region, 2019-2032 (USD Billion)

7. Global Myasthenia Gravis Disease Treatment Market, by Treatment

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 7.3. Surgery
    • 7.3.1. Global Myasthenia Gravis Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 7.4. Medication
    • 7.4.1. Global Myasthenia Gravis Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)
  • 7.5. HSCT
    • 7.5.1. Global Myasthenia Gravis Disease Treatment Market, by HSCT, by Region, 2019-2032 (USD Billion)

8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3. Online Pharmacies
    • 8.3.1. Global Myasthenia Gravis Disease Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Global Myasthenia Gravis Disease Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.5. Retail Pharmacies
    • 8.5.1. Global Myasthenia Gravis Disease Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)

9. Global Myasthenia Gravis Disease Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Myasthenia Gravis Disease Treatment Market - North America
    • 9.3.1. North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.2. North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3. North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.3.4. North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.3.5. Myasthenia Gravis Disease Treatment Market - U.S.
      • 9.3.5.1. U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.3.6. Myasthenia Gravis Disease Treatment Market - Canada
      • 9.3.6.1. Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.4. Myasthenia Gravis Disease Treatment Market - Europe
    • 9.4.1. Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.5. Myasthenia Gravis Disease Treatment Market - UK
      • 9.4.5.1. UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.6. Myasthenia Gravis Disease Treatment Market - France
      • 9.4.6.1. France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.7. Myasthenia Gravis Disease Treatment Market - Germany
      • 9.4.7.1. Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.8. Myasthenia Gravis Disease Treatment Market - Italy
      • 9.4.8.1. Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.9. Myasthenia Gravis Disease Treatment Market - Spain
      • 9.4.9.1. Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.10. Myasthenia Gravis Disease Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.11. Myasthenia Gravis Disease Treatment Market - Russia
      • 9.4.11.1. Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.5. Myasthenia Gravis Disease Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.5. Myasthenia Gravis Disease Treatment Market - China
      • 9.5.5.1. China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.6. Myasthenia Gravis Disease Treatment Market - India
      • 9.5.6.1. India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.7. Myasthenia Gravis Disease Treatment Market - Japan
      • 9.5.7.1. Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.8. Myasthenia Gravis Disease Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.9. Myasthenia Gravis Disease Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.10. Myasthenia Gravis Disease Treatment Market - South Korea
      • 9.5.10.1. South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.6. Myasthenia Gravis Disease Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.5. Myasthenia Gravis Disease Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.6. Myasthenia Gravis Disease Treatment Market - South Africa
      • 9.6.6.1. South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.7. Myasthenia Gravis Disease Treatment Market - Israel
      • 9.6.7.1. Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.8. Myasthenia Gravis Disease Treatment Market - UAE
      • 9.6.8.1. UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.7. Myasthenia Gravis Disease Treatment Market - Latin America
    • 9.7.1. Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.5. Myasthenia Gravis Disease Treatment Market - Mexico
      • 9.7.5.1. Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.6. Myasthenia Gravis Disease Treatment Market - Brazil
      • 9.7.6.1. Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.7. Myasthenia Gravis Disease Treatment Market - Argentina
      • 9.7.7.1. Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. AbbVie Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Alexion Pharmaceuticals, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Grifols, S.A.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Mylan N.V. (now part of Viatris Inc.)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Novartis AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Pfizer Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Regeneron Pharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Roche Holdings AG (including its subsidiary, Genentech)
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Takeda Pharmaceutical Company Limited
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Teva Pharmaceutical Industries Ltd.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제